Pharma ETFs Soar on Robust Q2 Earnings Sweta Killa - Zacks Investment Research - Fri Aug 7, 11:45AM CDT Sweta Killa - ZACKS - Fri Aug 7, 11:45AM CDT
Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress Zacks Equity Research - Zacks Investment Research - Fri Aug 7, 10:35AM CDT Zacks Equity Research - ZACKS - Fri Aug 7, 10:35AM CDT
Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.
Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus Kinjel Shah - Zacks Investment Research - Fri Aug 7, 10:30AM CDT Kinjel Shah - ZACKS - Fri Aug 7, 10:30AM CDT
Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates Zacks Equity Research - Zacks Investment Research - Fri Aug 7, 9:32AM CDT Zacks Equity Research - ZACKS - Fri Aug 7, 9:32AM CDT
Exelixis (EXEL) beats on earnings and sales in the second quarter.
Global Vaccines Industry Landscape 2020-2027: Increase in Incidence of Both Viral and Bacterial Infectious Diseases PR Newswire - PRF - Thu Aug 6, 1:45PM CDT CMTX - Thu Aug 6, 1:45PM CDT
, /PRNewswire/ -- The report has been added to offering.
Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss Zacks Equity Research - Zacks Investment Research - Thu Aug 6, 10:34AM CDT Zacks Equity Research - ZACKS - Thu Aug 6, 10:34AM CDT
Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.
Moderna (MRNA) Q2 Earnings and Revenues Surpass Estimates Zacks Equity Research - Zacks Investment Research - Thu Aug 6, 9:17AM CDT Zacks Equity Research - ZACKS - Thu Aug 6, 9:17AM CDT
Moderna (MRNA) reports narrower-than-expected second-quarter loss. Shares decline presumably on absence of any new data on coronavirus vaccine candidate.
Bristol-Myers (BMY) Q2 Earnings Beat, 2020 Earnings View Up Zacks Equity Research - Zacks Investment Research - Thu Aug 6, 8:57AM CDT Zacks Equity Research - ZACKS - Thu Aug 6, 8:57AM CDT
Bristol-Myers (BMY) beats on earnings and sales in the second quarter on the strength of Revlimid and Eliquis.
Colorectal Cancer Drugs Market Research Report by Class - Global Forecast to 2025 - Cumulative Impact of COVID-19 PR Newswire - PRF - Thu Aug 6, 7:35AM CDT CMTX - Thu Aug 6, 7:35AM CDT
, /PRNewswire/ --Read the full report: The Global Colorectal Cancer Drugs Market is expected to grow from in 2019 to by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 3.94%.Market Segmentation...
Global PD-L1 NSCLC Market: Insights, Epidemiology, Drugs and Players (2017-2030) PR Newswire - PRF - Thu Aug 6, 7:30AM CDT CMTX - Thu Aug 6, 7:30AM CDT
, /PRNewswire/ -- The drug pipelines has been added to offering.
Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs GlobeNewswire - Thu Aug 6, 7:05AM CDT CMTX - Thu Aug 6, 7:05AM CDT
- COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing -
Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark Zacks Equity Research - Zacks Investment Research - Wed Aug 5, 1:11PM CDT Zacks Equity Research - ZACKS - Wed Aug 5, 1:11PM CDT
Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.
Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates Zacks Equity Research - Zacks Investment Research - Wed Aug 5, 10:29AM CDT Zacks Equity Research - ZACKS - Wed Aug 5, 10:29AM CDT
Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.
Life Sciences Industry Leader Brian Kim Joins Summit Partners as Executive-in-Residence BusinessWire - Wed Aug 5, 9:25AM CDT CMTX - Wed Aug 5, 9:25AM CDT
Global growth equity investor Summit Partners today announced the addition of Brian Kim to the firm's Executive-in-Residence ("EIR") program. In this role, Mr. Kim will work closely with Summit's healthcare...
Merck Animal Health Completes Acquisition of IdentiGEN BusinessWire - Wed Aug 5, 6:00AM CDT CMTX - Wed Aug 5, 6:00AM CDT
Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its acquisition...
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Market 2020 with COVID-19 Impact Analysis Market Insight Reports - Wed Aug 5, 4:18AM CDT CMTX - Wed Aug 5, 4:18AM CDT
report by Marketinsightsreports offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Clostridium Difficile Infections (Clostridium Difficile...
3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio Benjamin Rains - Zacks Investment Research - Tue Aug 4, 6:44PM CDT Benjamin Rains - ZACKS - Tue Aug 4, 6:44PM CDT
Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries......
5 Growth ETFs & Stocks to Ride the Market Rally Sweta Killa - Zacks Investment Research - Tue Aug 4, 11:10AM CDT Sweta Killa - ZACKS - Tue Aug 4, 11:10AM CDT
Growth investing has taken the lead over value and is likely to stay given a slew of reasons.
Will Eliquis, Revlimid Drive Bristol-Myers (BMY) Q2 Earnings? Zacks Equity Research - Zacks Investment Research - Tue Aug 4, 9:04AM CDT Zacks Equity Research - ZACKS - Tue Aug 4, 9:04AM CDT
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH) BusinessWire - Tue Aug 4, 4:00AM CDT CMTX - Tue Aug 4, 4:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Hanmi Pharmaceutical today announced that the companies have entered into an exclusive licensing agreement for the development,...
